Zoledronic acid injection (Reclast, Novartis) has been approved as the first therapy to prevent postmenopausal osteoporosis for two years with a single dose.

In a study involving more than 500 postmenopausal women with osteopenia, a single infusion significantly increased bone mineral density at two years compared with placebo.

Read the rest of this entry »